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Abstract 
 
Biological variability (BV) has important applications in laboratory medicine.  It can be a 
source of variation in measured analyte values and provide guidance on reference 
interval use. BV has three components:  between-individual variation (CVg), caused by 
differences in mean values of a particular analyte among members of a group, within-
individual variation (CVi), caused by fluctuations around an individual’s inherent 
homeostatic set point, and analytical variation (CVa).  Thromboelastography (TEG), a 
type of viscoelastic coagulation analysis, is becoming increasingly common in veterinary 
referral centers.  Despite increased popularity, the optimal method of results 
interpretation is not clear.  While population-based reference intervals (PRI) are used for 
many analytes, reference change values (RCV) are more sensitive for disease detection 
for other analytes.  The relative sensitivity of PRI or RCV in detecting significant 
deviations of reported analyte values can be derived from BV data, via incorporation of 
CVi and CVg into a simple formula to calculate index of individuality (IOI). This study 
measured BV of four TEG variables R, K, angle and MA in clinically healthy horses and, 
using calculated IOI, found that population-based reference intervals are appropriate 
when interpreting results from individual animals.  Additionally, the ability to freeze a key 
reagent used in the TEG assay, tissue factor, was also investigated. 
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ABREVIATIONS AND SYMBOLS 
 
Alpha (α) Angle, a TEG variable  
BSA Bovine Serum Albumin       
BV                                Biological Variation 
CVa                               Analytical Variation 
CVg Between-group (or horse) Variation 
CVi Within-individual (or horse) Variation 
IOI Index of Individuality 
K Kinetics of fibrin formation, a TEG variable  
MA Mean amplitude, a TEG variable 
R Time until initial fibrin formation, a TEG variable 
RCV Reference Change Value 
PBS Phosphate-Buffered Serum 
PRI Population-based Reference Interval 
TEG Thromboelastography  
TF Tissue Factor 
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Chapter 1: Introduction   
 
     Variation is inherent to all laboratory measurements.  Even repeated measurements 
from one animal of unchanged health status, performed in the same laboratory using 
the same analytical methods, will often result in slightly different reported values.  
Causes of this variation include pre-analytical and analytical factors, such as differences 
in patient preparation, sample acquisition and handling, and instrument calibration.  An 
additional source of variation, not often considered in veterinary medicine, is biological 
variation (BV).  BV of a given analyte is assessed by measuring within-individual 
variation (CVi) and between-individual variation (CVg).  CVi is caused by natural 
fluctuations in an analyte’s concentration or activity relative to an individual’s 
homeostatic set-point.  CVg occurs between members of a group, all of whom have 
their own unique homeostatic set-points caused by differences in genetic makeup, 
environmental factors, and health status.1 
     Although population-based reference intervals (PRI) are often used to interpret 
laboratory data, a reference change value (RCV) may be a more sensitive means to 
detect medically significant deviations from “normal” for some analytes.2  A PRI, by 
convention, encompasses values from the central 95% of a reference sample 
population and defines an upper and lower reference limit.  Patient results falling 
outside of these limits are considered “abnormal” and are likely of medical significance.2  
As CVg increases relative to CVi, the central 95% of data also increases due to the 
wider range of measured values in the reference population.  It is possible for a PRI to 
be so wide that medically significant deviations from an individual’s set point will still fall 
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within the normal reference interval, rendering the PRI insensitive for disease detection.  
For these analytes, calculating reference change value  (a.k.a. critical difference or 
subject-based reference values) will likely be of benefit.  RCV defines the difference 
between two serial measurements from one individual that must be achieved for a 
change to be considered biologically significant, even if both results fall within a PRI.  
Recent papers describing biological variation in a healthy dog population and a reptile 
population concluded that results from most routine biochemical analytes and many 
coagulation tests are optimally interpreted using RCV, not population-based reference 
intervals.3,4,5   
     The index of individuality (IOI) is a standard formula that generates a unitless value 
used to predict the need for PRI or RCV based on CVg and CVi.6  When IOI for a 
particular analyte is over 1.4, population-based reference intervals are considered a 
sensitive means by which to interpret analyte data from individual animals.  When IOI is 
less than 0.6, reference change values are the more sensitive means to identify 
changes.  In order to apply BV to clinical interpretation of laboratory data, analytical 
variation (CVa) must also be known.  If CVa  is very high, medically important changes 
may become obscured in the wide range of values inherent to the particular analytical 
method.   Additionally, analytical variation is incorporated into the IOI formula and very 
large CVa values may impact calculated IOI.6   
     Viscoelastic coagulation analyzers are becoming increasingly common in veterinary 
tertiary referral centers, creating availability of these assays for some horse populations.  
Four commonly reported thromboelastography variables include the time to initial fibrin 
formation (R), kinetics of fibrin formation and clot development (K and angle, 
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respectively), and maximal clot strength (MA).7  A BV study on these TEG variables in 
dogs using a tissue factor-activated assay and frozen plasma, revealed a relatively 
small CVg and large CVi, suggesting that PRIs are appropriate for clinical interpretation 
of patient data.5  In contrast, a recent study in horses identified overlap of TEG data 
from healthy horses and horses with gastrointestinal disease; the extent to which BV 
may have contributed to these findings is not known.8 
     The main objective of this thesis work was to characterize biological variation 
(expressed as CVi and CVg) and analytical variation (CVa) of four TEG variables (R, K, 
angle and MA) in clinically healthy horses and to determine if use of population-based 
reference intervals is appropriate for clinical interpretation. 
     Before completing the biological variation study, investigation into the stability of a 
key reagent, Innovin (Dade-Behring, Marburg, Germany), was performed.  Innovin is a 
lyophilized reagent containing human recombinant tissue factor (TF), synthetic 
phospholipids, calcium and a mix of other stabilizers and buffers marketed for 
prothrombin time assay.9   Innovin has also been used to activate viscoelastic 
coagulation  assays, including  TEG assays.10,11,12  Benefits of TF-activated assays 
include faster reaction times and possibly improved precision and decreased intra-
operator variability.11,12,13  Although anecdotal reports suggest that freezing does not 
harm Innovin’s activity for purposes of TEG (CR Wagg, DACVP, e-mail 
correspondence, July 15, 2011; RC Carroll, PhD, e-mail correspondence, April 12, 
2013), the package insert warns it should not be frozen.  The ability to prepare aliquots 
and store TF prior to use would increase laboratory efficiency and potentially decrease 
costs associated with its use, but published data regarding the effects of freezing on TF 
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are not available.  The purpose of the first part of the thesis work was to determine if TF 
could be frozen for extended periods of time without loss of activity, as assessed by 
activation of a quality control material (Level II Control, Haemoscope, Niles, IL) and 
TEG. 
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Abstract 
Human recombinant tissue factor (TF) can be used to activate viscoelastic 
coagulation assays, including TEG.  Although the package insert of a commonly used 
product indicates that TF should not be frozen, published data supporting or refuting this 
claim are not available.  Ability to store frozen aliquots of TF would increase laboratory 
efficiency and decrease costs associated with performing TF-activated assays.  The 
objectives of this study were to determine the effects of freezing and storage time on 
TF’s ability to activate commercially available quality control material measured using 
TEG.  In order to accomplish this, TF was diluted and frozen at -20°C and -70°C for 0 
hours, 72 hours, 1 week, 2 weeks, 3 months and 6 months and its ability to activate 
control material was assessed.  TF activation of control material was also assessed 
after TF aliquots were held at room temperature for 0, 24 and 48 hours. Four TEG 
variables, R, K, alpha and MA were measured, and ANOVA used to identify differences.  
We found no significant differences in mean angle and MA regardless of storage time or 
temperature.  While mean values for R were not significantly increased at any time point 
when stored at room temperature or -70°C, significant increases in mean R were 
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observed for aliquots frozen at -20°C starting at the 1 week time point and continuing to 
the 6 months’ time point.  The data indicate TF can be stored at room temperature for at 
least 48 hours, stored at -20°C for 72 hours, and stored at -70°C for up to six months 
without significant loss of activity. 
 
Introduction 
     Quality control material II, (QCM II) is the abnormal quality control material that 
mimics hypocoagulability and is used .as part of a routine, daily protocol to assess TEG 
analytical performance.  QCM II rather than whole blood was used in this particular 
study because of two perceived advantages.  First, QCM II components in a given lot 
are expected to be constant.  In contrast, whole blood samples (even from the same 
individual) could be affected by biological variation, health status, hematocrit, sample 
handling, and other pre-analytical factors known to cause variation in TEG results.1,2  
The increased sample stability of QCM II made it more likely that we could isolate and 
identify effects of freezing while minimizing variation attributable to other sources.  
Second, use of QCM II also simplified experimental design.  The timing of assays was 
flexible, since QCM II could be prepared at any time, and animal use was precluded.   
The objectives of this study were to determine the effects of freezing and storage time 
on TF’s ability to activate commercially available quality control material (QCM II) 
measured using thromboelastography.    Information from Haemonetics personnel 
indicated that QCM II can be activated (Elaine Haney, MT, email communication, 
September 26, 2011) and this ability was verified prior to assessment of freezing on TF.  
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Materials and Methods 
      A pilot study demonstrated that TF could only activate QCM II when prepared by 
adding 2.0 mL sterile, deionized water to a 10.0 mL vial of lyophilized Innovin (Figure 1). 
TEG variables from QCM II samples with and without added TF were compared by 
using a single sample t-test of the hypothesis that the mean difference between pairs, 
on average, would be 0.  The normality assumption was met.  Since four t-tests were 
performed, a Bonferroni corrected significance value of 0.0125 was used. 
      Accordingly,  a 10 mL vial of TF was diluted using 2.0 mL sterile, deionized water, 
and aliquots of diluted TF were frozen at -70°C and -20°C or maintained at room 
temperature (21°C) until use.  Innovin aliquots were removed from the freezer after 72 
hours, 1 week, 2 weeks, 1 month, 3 months and 6 months, allowed to thaw and reach 
room temperature, and then used to activate QCM II.  The Innovin aliquots stored at 
room temperature were used immediately (0 hours) and after being stored, in a drawer 
away from light, for 24 and 48 hours.   
     For each TEG assay, 20 uL 0.2 M Calcium Chloride and 10 uL TF (i.e., diluted 
Innovin) were added to the reaction well first, followed by 330 uL of QCM II.  Weight of 
material in the Innovin vial is considered proprietary information, and the exact TF 
dilution achieved by reconstituting the 10 mL Innovin vial using 2.0 mL water could not 
be calculated.  If the dilution used is considered 1:2 (w/v), then the final dilution of TF in 
the sample cup was 1:72.  Temperature of the reaction well was 
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Figure 1:  Tissue factor activates quality control material II.   Bar graphs demonstrate 
that adding tissue factor (TF) to quality control material II (QCM II) significantly 
decreases R and K (p < 0.0001, for both; see A and B, respectively) and significantly 
increases angle (α; p < 0.0001; see C) but has no effect on MA (see D).  The label, 
QCM II, represents values obtained using quality control material alone, while bars 
labeled TF-QCM II represent values obtained by adding TF to QCM II.  
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                                            Figure 1. Continued.  
A. 
B. 
C. 
D. 
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was allowed to reach 37°C prior to adding any reagents and was maintained at 37°C for 
the duration of the assay. Assays were allowed to run until MA was finalized.  Machine 
balance and e-test were assessed daily prior to sample analysis, according to 
manufacturer instructions.  Additionally, TEG analytical performance was monitored 
daily prior to sample analysis, using two-level (normal and abnormal) quality control 
materials (Level I Control and Level II Control, respectively, Haemoscope,  Niles, IL) run 
in duplicate.  All QCM used in this study, both as daily control and experimental 
samples, were prepared according to manufacturer’s instruction and were of the same 
lot.  Control data were considered acceptable if results fell within manufacturer-provided 
ranges for each control material.  All data were collected electronically using instrument 
software (TEG Analytical Software Version 4.2, Haemonetics Corporation, Braintree, 
MA).  Each TEG assay was completed by one operator (JLS) and performed in 
replicate; the average of the replicates was used for statistical analysis. 
 
     Statistical Analysis 
Statistical analysis was performed using SAS/Stat software (SAS Institute Inc., 
Version 9.3 SAS for Windows, Cary, NC, 2010).  ANOVA was used for means 
comparisons.  Values of p < 0.05 were considered significant.  A Bonferroni adjustment 
for multiple comparisons was used when appropriate.  When significant effects were 
found, means were separated by use of the least significant difference test.  The 
Shapiro-Wilk statistic was used to test normality of residuals from each ANOVA.  The 
assumption of equal variances was tested using the Levene’s F test. Since assumptions 
were not adequately met, rank transformed data were used in all reported analyses. 
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Results 
For Innovin aliquots stored at room temperature for 0, 24 and 48 hours, no 
significant differences were found in mean R, angle, or MA (p = 0.65, p = 0.81 and p = 
0.68, respectively; data not shown).  The mean value for K was the same at all time 
points, precluding analysis.  For Innovin aliquots stored at -20°C and -70°C and freshly 
reconstituted Innovin (room temperature, 0 hours), effects of time and temperature were 
assessed for R, angle and MA.  Values for K were the same at all time and temperature 
combinations and not analyzed further.  There were no significant differences in mean 
angle and mean MA regardless of storage time or temperature (p = 0.43 and p = 0.067, 
respectively; Figure 2). There was a significant interaction of time and temperature for R 
(p < 0.0001; Figure 2).  While mean values for R were not significantly increased at any 
time point when stored at -70°C, significant increases in mean R were observed for 
aliquots frozen at -20°C starting at the 1 week time point and continuing to the 6 
months’ time point (p < 0.05).  Mean R obtained using freshly reconstituted Innovin 
(room temperature, 0 hours) did not differ significantly from means obtained when 
Innovin was stored at -20°C for 72 hours.   
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Figure 2:  Freezing effects tissue factor’s ability to activate quality control material II.   
Line graphs demonstrating effects of freezing at two different temperatures on tissue 
factor’s (TF) ability to activate quality control material II.  A significant time by 
temperature interaction was found for R when TF was stored at -20°C (p < 0.0001; see 
A); R times increased starting at the 1 week (1 w) time point and continuing through the 
six month (6m) time point.  A significant time by temperature interaction was not found 
for angle (α; p = 0.43; see B) or MA (p = 0.07; see C).   The 0h time point reflects values 
obtained from using fresh, never frozen, TF.  The other time points reflect length of time 
TF was frozen (h = hours, w = weeks, m = months).  
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                                         Figure 2. Continued 
A. 
B. 
C. 
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Interpretation 
     Diluted Innovin can be frozen at -70°C for up to 6 months without significant loss of 
activity and at -20°C for up to 72 hours without significant loss of activity.  Consistent 
with information in the Innovin package insert indicating that reconstituted TF is stable 
up to five days at temperatures between 15° and 25°C, we observed TF can be stored 
at least for 48 hours at room temperature (21°C).3    
 
Discussion 
     As the matrix and composition of one lot of QCM material are expected to be 
constant, any changes in tracings in our assay are presumed due to the addition of the 
activator and its specific effects.  The variable R is measured in minutes, reflects the 
time between assay initiation and initial fibrin polymerization, and is very much 
dependent on the rate of thrombin formation.4  The variable K is also measured in 
minutes and is the time from R until an amplitude of 20 mm is reached on the TEG 
tracing.  In whole blood samples, K is dependent on factors II and VIII, fibrinogen, 
platelet count and function, hematocrit and thrombin formation.5   
     The TF used in this assay was much more concentrated than typically used with 
whole blood TEG assays and likely rapidly initiated and maximized formation of the 
tissue factor-Factor VII complex, resulting in a substantial and speedy thrombin burst.  
This thrombin burst, in turn, increased kinetics of fibrin polymerization, shortening R 
time in the activated QCM II assay.  Freezing at -20°C presumably resulted in partial 
degradation or inactivation of TF that became more pronounced the longer TF was 
frozen, resulting in less initial thrombin formation and subsequent increasing R times.  A 
18 
 
study by Smith et al, using canine citrated whole blood, observed that the ROTEM 
variable CFT (the equivalent of K) seemed less sensitive to changes in concentration 
than did CT (the equivalent of R), suggesting that  small changes in TF concentration 
due to freezing would most likely manifest as changes in R and not K. 6  It also seems 
plausible that the large TF concentration used in our study exceeded that required to 
maximize K; this could explain why K values were identical for all TF aliquots, 
regardless of storage time or temperature.  
     Although we did not observe a significant effect of freezing at -70°C, it is possible 
that a small amount of TF did degrade but our assay was not sensitive enough to 
identify this change.  Previously reported whole blood assays use more dilute TF 
concentrations than used in this study, and it is possible that small losses of TF activity 
induced by freezing could impact R (and possibly other variables) in such whole blood 
assays.7, 8, 9  Further studies could potentially better characterize effects of freezing TF 
by investigating activity of more concentrations of TF than assessed in our study.  
Ideally, such studies should involve activation of whole blood samples; however, sample 
stability issues make design of such studies challenging.  Based on the data presented 
above, we suggest that freezing Innovin at -70°C for up to six months is possible, while 
freezing at -20°C is recommended for only 72 hours or less.  Accordingly, we prepared 
a large batch of dilute tissue factor and froze aliquots in preparation for the second 
study presented in this thesis. 
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Abstract 
     Thromboelastography (TEG), a type of viscoelastic coagulation analysis, is 
becoming increasingly common in veterinary referral centers.  Despite increased 
popularity, the optimal method of results interpretation is not clear.  While population-
based reference intervals (PRI) are used for many analytes, reference change values 
(RCV) are more sensitive for disease detection for other analytes.  The relative 
sensitivity of PRI or RCV in detecting significant deviations of reported analyte values 
can be derived from BV data, via incorporation of CVi and CVg into a simple formula to 
calculate index of individuality (IOI). Analytical variation is also incorporated into this 
formula.  BV of four TEG parameters R, K, angle and MA were measured in ten 
clinically healthy horses, and within- and between-horse biological variation (CVi and 
CVg, respectively) and analytical variation (CVa) were calculated using a nested 
ANOVA after removing outlier data.  Index of individuality was then calculated.  Results 
indicate that population-based reference intervals are appropriate for TEG variables R, 
angle and MA when interpreting results from individual horses.  Population-based 
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reference intervals are likely appropriate when interpreting K, but IOI could not be 
calculated for this variable.   
 
Introduction 
     Biological variability (BV) has important applications in laboratory medicine.  It can 
be a cause of variation in analyte values and provide guidance on reference interval 
use. BV has three components:  between-individual variation (CVg), caused by 
differences in mean values of a particular analyte among members of a group, within-
individual variation (CVi), caused by fluctuations around an individual’s inherent 
homeostatic set point, and analytical variation (CVa).1  Although BV data are commonly 
investigated in human medicine, they are less emphasized in veterinary species.   
     The optimal method of results interpretation of TEG data is not clear.  While 
population-based reference intervals (PRI) are used for many analytes, reference 
change values (RCV) are more sensitive for disease detection for other analytes.  The 
relative sensitivity of PRI or RCV in detecting significant deviations of reported analyte 
values can be derived from BV data, via incorporation of CVi and CVg can into a  simple 
formula to calculate index of individuality (IOI).  This section of the  thesis reports 
measured BV of the four TEG parameters R, K, angle and MA, and calculated IOI,  in 
clinically healthy horses.   
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Materials and Methods 
Animals and sample handling 
     This prospective study was conducted over a five week period using ten  healthy 
horses randomly pulled from a research and teaching herd.  Animal use and sampling 
of blood was approved by the Institutional Animal Care and Use Committee of The 
University of Tennessee (protocol number 2097-0612).  Horses ranged in age from 8-15 
years, were mares, and included two Quarter horses, two Tennessee Walking Horses, 
one Missouri Fox Trotter, and five mixed breed horses.  Horses were housed on pasture 
with free access to water and were fed free choice, mixed grass hay daily.  Animal 
health was assessed one week prior to beginning the study using physical examination 
by a board-certified large animal internist (KM) and routine laboratory evaluation 
consisting of a CBC (including platelet count; ADVIA 120, Bayer HealthCare LLC, 
Tarrytown, NY ), biochemical testing (Cobas c 501, Roche Diagnostics, Indianapolis, 
IN), and coagulation analysis (STA Compact, Diagnostica Stago, Parsippany, NJ).  
Blood smear review accompanied each CBC.  Coagulation analysis consisted of 
prothrombin time, partial thromboplastin time, and fibrinogen concentration.  Inclusion 
criteria required horses to have an unremarkable physical examination and medical 
history, laboratory values that were within institutional equine reference intervals, and 
no medication administration in the previous two weeks.  Medications were not 
administered during the course of the study. 
Horses were stall-confined overnight and fasted for approximately ten hours prior 
to each blood sampling event; blood was collected from each horse once weekly for five 
weeks by two large animal internists.  To minimize pre-analytical variation, all samples 
25 
 
were taken between 7:00 and 11:00 a.m. and were obtained from a jugular vein directly 
into a 3.2% citrated vacutainer tube (BD Vacutainer Evacuated Citrate Tube, Vacutainer 
Holder, and Precision Glide needles, Becton, Dickinson, and Company, Franklin Lakes, 
NJ) using a vacuum collection system and 1.5" 20 g needle.2,3  The jugular vein used 
was alternated each week.  Blood samples were maintained at room temperature for 
approximately 30 minutes from the time of collection to the start of the TEG assay (TEG 
5000, Haemoscope Corporation, Niles, IL) to mitigate variations in results due to 
different storage times.4,5 
 
Thromboelastography 
     A tissue factor (TF)-activated TEG assay performed at 37C was used throughout 
the study.  TF (Innovin, Dade-Behring, Marburg, Germany) was diluted using 
phosphate-buffered saline (PBS; PBS powder, pH 7.4, Sigma-Aldrich, St. Louis, MO ) 
and bovine serum albumin (BSA; BSA 30% solution, Sigma-Aldrich, St. Louis, MO) 
according to previously published protocols.6  Weight of material in the TF vial is 
considered proprietary information, and the exact TF dilution achieved by reconstituting 
the 10 mL Innovin vial using 2.0 mL sterile, deionized water could not be calculated.  If 
the dilution used is considered 1:2 (w/v), and the subsequent dilution created by adding 
an aliquot of the prepared Innovin to the BSA/PBS solution considered 1:50, the final 
dilution is estimated to be 1:100.  TF target concentration in the TEG sample cup was 
1:3600.  Based on a study in our laboratory (see Chapter 2) and consultation with other 
investigators (personal communication: Catherine R. Wagg, Faculty of Veterinary 
Medicine, University of Calgary, Calgary, Canada, 2011 and Roger C. Carroll, Graduate 
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School of Medicine, University of Tennessee, Knoxville, TN, 2013), TF is stable for at 
least six months when frozen at -70°C.  Accordingly, TF was prepared prior to the start 
of the study and aliquots stored at -70°C until use. 
     For each individual TEG assay, the reaction cup held 10 L of diluted TF (thawed to 
room temperature immediately prior to use), 20 uL of 0.2 M CaCl2 (Haemonetics 
Corporation, Niles, IL) and 330 L of citrate-anticoagulated whole blood.  TF and 
calcium solutions were added to the reaction cup first, and whole blood was added 
when the temperature of the cup returned to 37°C.  Contents of the reaction cup were 
immediately and gently mixed using re-aspiration into the pipette tip to ensure adequate 
mixing of all components before each TEG assay was started.7  All samples were run in 
duplicate. 
     Machine balance and e-test were assessed daily prior to sample analysis, according 
to manufacturer instructions.  TEG analytical performance was monitored daily, using 
two-level (normal and abnormal) quality control materials (Level I Control and Level II 
Control, respectively, Haemonetics Corporation, Braintree, MA) run in duplicate.  
Control data were considered acceptable if results fell within manufacturer-provided 
ranges for each control material.  All data were collected electronically using instrument 
software (TEG Analytical Software Version 4.2, Haemoscope Corporation, Braintree, 
MA). To minimize pre-analytical and analytical variation, all TEG assays (including 
control runs) were performed by one individual (JLS), and all reagents and supplies 
used during the course of the study were from one lot number, respectively. 
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Statistical Analysis 
     Statistical analyses were conducted using computer software (SAS Institute Inc., 
Version 9.3 SAS for Windows, Cary, NC) and an approach for biological variation 
suggested by Fraser and Harris.3,8  The data were screened for outliers, first using the 
Cochran’s C test to identify outliers in the duplicate results and then in the variance of 
subject means.  Values for R and K from one horse obtained during week 3 were 
excluded as a result of this analysis.  Reed’s criterion was then used to identify 
individuals with overall mean values for R, K, angle and MA that differed from all other 
subject’s means.  Values for MA from one horse were subsequently excluded from 
further analysis.  Between-horse variance, within-horse variance, and analytical 
variance were then obtained for each measurement using a nested ANOVA.  Variances 
and the overall mean for each measurement were used to calculate the corresponding 
coefficients of variation, CVi, CVg and CVa.  Values of P < 0.05 were considered 
significant for all statistical tests. 
     The index of individuality (IOI) was calculated using the formula 
    √ 
   
       
    
 
where CVi is within-horse variation, CVg is between-horse variation and CVa is 
analytical variation. 
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Results 
Study population 
     All horses used in the study were healthy on physical examination and had 
hematologic, biochemical, and coagulation parameters that were within institutional 
equine reference intervals (data not shown). 
 
Biologic Variation and IOI of TEG variables 
     CVi (%) for TEG variables R, K, Angle and MA are 26.8, 31.0, 9.4 and 3.4, 
respectively.  CVg (%) for R, K, Angle and MA are 5.2, 0.0, 6.2 and 4.1, respectively.  
CVa (%) for R, K, Angle and MA are 5.9, 5.9, 21.7, 4.4, respectively.  Calculated IOI for 
R, K, Angle and MA are 5.3, not assessed, 3.8 and 1.4, respectively (see Table 1).   
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Table 1:  Biological variation data and IOI of four TEG variables in 10 healthy horses.  
 
 
Table 1.  Summary of CVi, CVg, CVa and calculated IOI.  The total number of samples 
is the number collected from all horses over the course of the experiment after removing 
outliers.  NA – not assessed 
 
 
 
 
 
 
 
 
TEG variable CVi (%) CVg (%) CVa (%) IOI Total # samples 
R 26.8 5.2 5.9 5.3 47 
K 31.0 0.0 5.9 NA 47 
Angle 9.4 6.2 21.7 3.8 48 
MA 3.4 4.1 4.4 1.4 43 
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Discussion 
     Biological variation estimates in people are made in clinically healthy individuals, 
even though resulting data are intended to be applied to all populations (sick, adult, 
geriatric, etc.).1,3,8-10  Although mean values for laboratory results can vary by sex, 
health status, breed, and age, the inherent biological variability around a given 
homeostatic set point appears constant, even in chronic disease states.11-15  This 
suggests that BV data from our study are likely applicable to most horses, not just 
healthy, non-athletic mares. 
     Studies in humans indicate biological variation does not change significantly in 
disease; however, most data concerning non-healthy individuals were obtained from 
patients with chronic, stable diseases, not acute disease or emergent conditions.  It 
seems plausible that, in acute disease, acute decompensation of chronic disease, or 
during times of growth and development (i.e., when measured homeostatic set points 
may be in flux), that BV may be greater than it is in steady states (health or chronic, 
stable disease).  There is no prior published information regarding biological variation of 
TEG variables in horses in either health or disease, so it is not clear how or if BV might 
change in different homeostatic or pathologic conditions in horses.  It is important to 
remember, particularly in the context of viscoelastic coagulation analysis, that changes 
in hematological variables influence patient data.  For example, studies investigating 
effects of erythrocyte mass on thromboelastometry (ROTEM™) have shown that there 
is an inverse relationship between hematocrit and coagulability.  Tracings appear 
hypocoagulable as hematocrit increases and hypercoagulable as hematocrit 
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decreases.16,17  Erythrocyte and platelet mass changes occur in many critical care 
patients and have potential to affect results of viscoelastic testing. 
     Index of individuality (IOI) is a unitless index derived from a calculation using CVa, 
CVi and CVg.  By convention, when the resulting number is greater than 1.4, 
population-based reference intervals are considered acceptable for clinical 
interpretation.  When IOI is less than 0.6, use of RCV to interpret patient data is 
considered optimal.  Results from this study suggest that R, K and angle data can be 
appropriately interpreted using PRIs.  IOI for MA was exactly 1.4; PRIs are likely 
appropriate for this variable as well, but a small, clinically significant change may not be 
as easily detected as if IOI were greater.  IOI for K is listed as NA (see Table 1).  This is 
because the variation attributable to K’s CVg was zero, and CVg is in the denominator 
of the IOI formula; a number divided by zero is indeterminate.  If CVg were very small 
(approaching zero but with a numeric value), the resulting IOI would be much greater 
than 1.4. 
     CVa was highest for angle (21.7 % vs. all other values less than 6.0%).  The exact 
reason for this is not clear.  It is possible that TF-activated TEG is not the optimal way to 
measure this particular variable, and that another method may increase precision.  Our 
controls were within limits for all variables, suggesting analytical error did not contribute 
to the variation in angle.  Additionally, CV calculated using quality control material (QCM 
I) for angle was less than 0.4%, perhaps suggesting whole horse blood has components 
or matrix effects that caused the relatively high CVa associated with angle 
measurement.  The addition of TF has been reported to decrease analytical variability in 
TEG results.18  It could be that increasing TF concentration beyond that used here may 
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decrease angle variability.  A consequence of the high CVa for angle is that the degree 
of analytical variation may make it difficult to identify small, medically significant, 
changes in that variable. 
     Fraser and Harris and others advocate the ideal biological variation study would 
involve all samples being collected and then stored under conditions ensuring sample 
stability until one large analytical run can be performed.3,10  This design is favored 
because it mitigates the effect of between-run analytical variation on results.   Due to 
the inherent sample instability associated with whole blood TEG assays and an inability 
to freeze whole blood intended for TEG analysis, a limitation of this study is that we 
analyzed samples in different runs, 30 minutes after collecting the blood.4,5,19  Although 
not the ideal approach, this experimental design is often used in instances where 
sample instability precludes long term storage 8,3  An advantage of our design is that it 
mirrors how TEG is performed in many routine clinical situations. 
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Chapter IV:  Conclusions 
 
The first part of this thesis provides information regarding stability of a key TEG 
assay component, tissue factor.  The data indicated tissue factor can be frozen at 
 -70°C for at least 6 months.  Accordingly, a large batch of TF was prepared and  
aliquots frozen for the subsequent biological variation study.  The second part of this 
document describes biological variation and analytical variation for the TF-activated 
TEG variables, R, K, angle and MA, in healthy horses.  Incorporation of the BV and CVa 
data into the index of individuality formula demonstrates that population-based 
reference intervals are an appropriate way to interpret TF-activated TEG data from 
individual horses.    
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